137 related articles for article (PubMed ID: 28867729)
1. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Mitsuboshi S; Yamada H; Nagai K; Okajima H
Biol Pharm Bull; 2017; 40(9):1463-1467. PubMed ID: 28867729
[TBL] [Abstract][Full Text] [Related]
2. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
3. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Sezai A; Obata K; Abe K; Kanno S; Sekino H
Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
6. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis.
Nagaoka Y; Tanaka Y; Yoshimoto H; Suzuki R; Ryu K; Ueda M; Akiyama M; Nagai M; Miyaoka Y; Kanda E; Iwai S; Nagaoka M; Kanno Y
Hemodial Int; 2018 Jul; 22(3):388-393. PubMed ID: 29227568
[TBL] [Abstract][Full Text] [Related]
7. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
8. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.
Tanaka A; Nakamura T; Sato E; Node K
Drugs R D; 2017 Mar; 17(1):97-101. PubMed ID: 28074335
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya T; Sasaki T; Ohashi T
Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
[TBL] [Abstract][Full Text] [Related]
12. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
[TBL] [Abstract][Full Text] [Related]
13. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
14. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
15. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
Tohyo S
Int J Clin Pharmacol Ther; 2019 Nov; 57(11):567-570. PubMed ID: 31496508
[TBL] [Abstract][Full Text] [Related]
16. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Ohta Y; Ishizuka A; Arima H; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
Hypertens Res; 2017 Mar; 40(3):259-263. PubMed ID: 27760998
[TBL] [Abstract][Full Text] [Related]
17. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
18. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
19. Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Alshahawey M; Shahin SM; Elsaid TW; Sabri NA
Am J Nephrol; 2017; 45(5):452-459. PubMed ID: 28463849
[TBL] [Abstract][Full Text] [Related]
20. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
